Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

the completion of the Phase 1 clinical trials for AT2220 for the treatment of Pompe disease, the start of Phase 2 studies for AT2220 and the possibility and timing of conducting clinical trials of AT2220 and ERT combination therapy; (ii) statements regarding the timing and goals of discussions with US and EU regulatory authorities on the Phase 3 study and regulatory pathway for Amigal; (iii) statements on the goals, progress and timing of preclinical studies in Parkinson's disease and other research efforts aimed at evaluating disease targets in neurodegenerative and metabolic disorders; (iv) statements on the range of "cash burn" for Amicus in 2008, the need to raise additional capital in 2008 and the trends for incurring research and development expense in 2008; and (v) statements regarding expected milestone and research reimbursement payments from Shire. These forward looking statements are based on the current estimates and assumptions of the management of Amicus as of the date of this press release and the conference call and are subject to risks, changes in circumstances, assumptions and uncertainties and other factors that may cause the actual results of Amicus to be materially different from those reflected in the forward looking statements. Important factors that may cause actual results to differ materially from those indicated by forward looking statements include, among others, the potential that results of clinical or preclinical studies indicate that product candidates are unsafe or ineffective, our dependence on third parties in the conduct of our clinical studies, delays or failure to achieve regulatory approvals, risks of relying on third party manufacturers for the supply of our product candidates, we or our licensors may not be able to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of our product candidates and risks of collaborating with third parties to develop and commercialize products. Th
'/>"/>
SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... USA (PRWEB) September 20, 2014 Entries ... 2015 Prism Awards for Photonics Innovation . The ... the multi-billion dollar optics and photonics industry, and is ... and photonics , and Photonics Media . , ... the versatility of photonics, said SPIE CEO Eugene Arthurs. ...
(Date:9/19/2014)... YORK, September 18, 2014 Scientists at NYU Langone ... dramatically the efficiency of the process for turning adult ... well-known compounds, including vitamin C. Using the new technique ... cells obtained from adult skin cells by more than ... technique is efficient and reliable, and thus should generally ...
(Date:9/19/2014)... FRANCISCO , Sept. 19, 2014  Nektar ... results from preclinical studies characterizing the analgesic profiles ... peripherally-acting kappa opioid receptor agonist molecules. The preclinical ... polymer medicinal chemistry platform. The analgesic ... in the medical literature. 1,2 Kappa opioid ...
(Date:9/19/2014)... , September 19, 2014 ... Markets ( http://www.researchandmarkets.com/research/b2jxhs/micro_market ) has announced the addition of ... Columns"  report to their offering.       ... is one of the fastest-growing segments in the ... billion in 2013, and expected to reach $2.0 ...
Breaking Biology Technology:Entry deadline is 10 October for international photonics Prism Awards 2Entry deadline is 10 October for international photonics Prism Awards 3Entry deadline is 10 October for international photonics Prism Awards 4NYU Langone scientists report reliable and highly efficient method for making stem cells 2NYU Langone scientists report reliable and highly efficient method for making stem cells 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Micro Market Monitor : Global Pre-packed Chromatography Columns 2
... /Xinhua-PRNewswire-FirstCall/ --,China Biologic Products, Inc. (OTC Bulletin Board: ... plasma-based pharmaceutical companies in the,People,s Republic of China ... from the Guangxi Province Bureau of Health, to ... Bei County, Guangxi Province., The new plasma ...
... June 30 Cardiac Science,Corporation (Nasdaq: CSCX ... rehabilitation, and informatics products, announced today,that it has ... The Company,s,addition to the Russell 3000 Index was ... 27. Selection to the Russell 3000 index means ...
... Pharmaceuticals,(Nasdaq: SGXP ) today announced that it ... the U.S. Food and Drug Administration for SGX393.,This ... for the treatment of relapsed and refractory chronic,myelogenous ... CML is Gleevec(R). Although Gleevec is a,highly effective ...
Cached Biology Technology:China Biologic Products Announces Approval for Setting Up a New Plasma Collection Station in Pu Bei County, Guangxi Province 2China Biologic Products Announces Approval for Setting Up a New Plasma Collection Station in Pu Bei County, Guangxi Province 3Cardiac Science Announces Inclusion in Russell 3000 Index 2SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393 2SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393 3
(Date:9/18/2014)... moon of Uranus, is one of the most visually ... its relatively small size, Miranda appears to have experienced ... formation of at least three remarkable and unique surface ... coronae are visible in Miranda,s southern hemisphere, and each ... the largest, has ridges and troughs with up to ...
(Date:9/18/2014)... No matter how many times it,s demonstrated, ... communicating creatures. , But by using a ... radically alter their behavior to suit their population. ... them are present, and act accordingly. , Once ... it may change from innocuous to pathogenic, or ...
(Date:9/18/2014)... AZ, Sept. 18, 2014 -- Arizona turned its newborn ... just a few short months, earning it the first-ever Newborn ... The March of Dimes presented Will Humble, M.P.H., Arizona,s Department ... held here today. Mr. Humble established a policy of full ... to send newborn blood samples to the lab for analysis, ...
Breaking Biology News(10 mins):Miranda: An icy moon deformed by tidal heating 2Miranda: An icy moon deformed by tidal heating 3Miranda: An icy moon deformed by tidal heating 4Miranda: An icy moon deformed by tidal heating 5Miranda: An icy moon deformed by tidal heating 6Miranda: An icy moon deformed by tidal heating 7Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 3
... Jan. 25, 2013 /PRNewswire-iReach/ --   Find Heather ... Hildreth . She is a a third year physics major at ... has also learned after writing numerous twenty plus page lab reports, a ... pursue a career relating to patents and IP law. Last summer, she ...
... Zhen Huang freely admits he was not interested in ... development in a fetal mouse. Instead, he wanted to ... glia would affect the growth of neurons. The ... it begged for explanation. "It was a surprising ...
... billion people by 2050, humanity faces the challenge of feeding ... of water, fertilizer and arable land as today. Cornell ... by discovering a gene that could lead to new varieties ... gene, called Scarecrow, is the first discovered to control a ...
Cached Biology News:The Website You Have to Log Into 2The Website You Have to Log Into 3Chance finding reveals new control on blood vessels in developing brain 2Newly discovered 'scarecrow' gene might trigger big boost in food production 2
... The ProteoSpin Detergent Clean-up Micro Kit provides ... removal of SDS, Triton X-100 and other detergents ... spin-column chromatography using Norgens patented protein resin as ... processing 2 50 g of either acidic or ...
Compound(s) screened through any number of client selected assays. Client also selects number of concentrations and replicates....
... hematopoietic stem cells called monocytes. Osteoclasts resorb ... and lowering the surrounding pH to an ... mineral is then solubilized and the collagen ... primarily by Macrophage Colony-Stimulating Factor (M-CSF) and ...
Values of steady state parameters for enzyme activities are determined....
Biology Products: